1-20 of 130 results for subject:"Atrial fibrillation"
Librarians' tools
- Search time
- 0.29 seconds
- Solr query time
- 0.005 seconds
- Search query
- subject:"Atrial fibrillation"
- We searched for
- subject_t:"Atrial fibrillation" OR subject_ses:422869
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of patients with atrial fibrillation who are unable to take long-term anticoagulation for the prevention of strokes in (a) Slough and (b) the South East.
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of patients with atrial fibrillation who are unable to take long-term anticoagulation for the prevention of strokes in (a) Slough and (b) the South East.
No estimate has been made regarding the number of patients with atrial fibrillation who are unable to take long-term anticoagulation for the prevention of strokes in Slough and the South East as this information is not collected. However, clinical consensus suggests that less than 10% of patients with atrial fibrillation have clear contraindications to the use of long-term anticoagulation.
This Government recognises the importance of optimising atrial fibrillation treatment, which can reduce the risk of stroke by up the 64%. The Department and NHS England continue to look to NICE for guidance on the role of long-term anticoagulation for the prevention of strokes, and the approach for those who are unable to take long-term anticoagulation.
Alongside this, the Department will publish the Cardiovascular Disease Modern Service Framework soon, to support greater consistency in the detection, assessment, management and treatment of cardiovascular disease across England.
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of atrial fibrillation patients eligible for a left atrial appendage occlusion procedure in (a) Slough and (b) the South East.
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of atrial fibrillation patients eligible for a left atrial appendage occlusion procedure in (a) Slough and (b) the South East.
Left atrial appendage occlusion (LAAO) is a prescribed specialised service and is commissioned in accordance with NHS England’s published national clinical commissioning policy, which is available at the following link:
NHS England’s regional specialised commissioners and integrated care boards are responsible for the monitoring of activity, reviewing of equity of access for their populations, and addressing variation through local oversight and clinical networks. Therefore, assessment would best be made at local levels.
For the same reason, information on the number of patients eligible for LAAO in Slough or the South East is not held centrally by the Department.
To ask the Secretary of State for Health and Social Care, what recent assessment has been made of the availability of left atrial appendage occlusion procedures to eligible patients in the South East.
To ask the Secretary of State for Health and Social Care, what recent assessment has been made of the availability of left atrial appendage occlusion procedures to eligible patients in the South East.
Left atrial appendage occlusion (LAAO) is a prescribed specialised service and is commissioned in accordance with NHS England’s published national clinical commissioning policy, which is available at the following link:
NHS England’s regional specialised commissioners and integrated care boards are responsible for the monitoring of activity, reviewing of equity of access for their populations, and addressing variation through local oversight and clinical networks. Therefore, assessment would best be made at local levels.
For the same reason, information on the number of patients eligible for LAAO in Slough or the South East is not held centrally by the Department.
To ask the Secretary of State for Health and Social Care, what recent estimate has been made of the number of patients with atrial fibrillation in (a) Slough and (b) the South East.
To ask the Secretary of State for Health and Social Care, what recent estimate has been made of the number of patients with atrial fibrillation in (a) Slough and (b) the South East.
The Department has not made a recent estimate. Information on the percentage of patients with atrial fibrillation, as recorded on practice disease registers, for local areas is available on the Department’s Fingertips website, at the following link:
https://fingertips.phe.org.uk/search/atrial%20fibrillation
To ask the Secretary of State for Health and Social Care, what steps he is taking to help reduce waiting times for atrial fibrillation ablation procedures in (a) Yeovil constituency, (b) Somerset and (c) England.
To ask the Secretary of State for Health and Social Care, what steps he is taking to help reduce waiting times for atrial fibrillation ablation procedures in (a) Yeovil constituency, (b) Somerset and (c) England.
Catheter ablation for paroxysmal and persistent atrial fibrillation for adults is a prescribed specialised service commissioned in accordance with a published national clinical commissioning policy. Consequently, NHS England’s regional specialised commissioning teams and integrated care boards (ICBs), including the Somerset ICB, are responsible for monitoring activity, reviewing equity of access for their populations, and addressing unwarranted variation through local oversight arrangements and clinical networks.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help address variations in access to care for people with atrial fibrillation in England.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help address variations in access to care for people with atrial fibrillation in England.
NHS England commissions the CVDPREVENT audit, which publishes routinely held general practice data to support planning and tackle unwarranted variation at national, regional, integrated care board, primary care network, and practice level. This includes information on atrial fibrillation treatment.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve outcomes for patients with atrial fibrillation in Camborne and Redruth constituency.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve outcomes for patients with atrial fibrillation in Camborne and Redruth constituency.
The National Health Service in Cornwall has a comprehensive cardiovascular training programme in place for primary care staff. This is a key initiative to increase awareness of prevention, cause and management of stroke, atrial fibrillation, acute coronary syndromes and heart failure.
The NHS locally report over nine in ten patients with atrial fibrillation in Camborne and Redruth are treated with anti-coagulants, with treatment rates having increased across Cornwall over the last three years with biggest increases in areas with highest deprivation.
The NHS in Cornwall is also working to prevent, identify and treat linked conditions such as diabetes, alcohol dependency and high blood pressure and to support lifestyle changes that can improve atrial fibrillation symptoms, coronary heart disease, strokes and transient ischemic attacks as well as other cardiovascular conditions such as peripheral arterial disease.
To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into atrial fibrillation in the 2023-24 financial year; and which public bodies provided that funding.
To ask the Secretary of State for Science, Innovation and Technology, how much funding the Government provided for research into atrial fibrillation in the 2023-24 financial year; and which public bodies provided that funding.
The Department of Health and Social Care (DHSC) funds medical research through the National Institute for Health and Care Research (NIHR). Between 2019/20 – 2023/24, the NIHR has invested £145.4 million on cardiovascular disease and stroke research directly through NIHR research programmes.
UKRI delivers a substantial portfolio of researcher-led projects. UKRI’s Medical Research Council (MRC) also plays a key role in funding underpinning research which may not be attributable to a specific condition but will benefit medical research more generally.
In 2024 MRC established a new Centre of Research Excellence (MRC CoRE), co-funded with the British Heart Foundation (BHF) called the MRC/BHF CoRE in Advanced Cardiac Therapies, which will receive up to £50 million over 14 years. The Centre will focus on developing gene therapies for heart disease, including aiming to develop the first therapies to stimulate heart repair and regeneration. The new MRC CoRE funding model aims to support transformative approaches in biomedical and health research.
Details of UKRI and NIHR funding on specific areas is provided in the table below:
| NIHR funding in FY 2023/24 | UKRI Funding in FY 2023/24 |
Hypertrophic obstructive cardiomyopathy | NIHR did not commit any specific funding for obstructive cardiomyopathy research in the 2023-24. | UKRI did not commit any specific funding for obstructive cardiomyopathy research in 2023-24. |
dilated cardiomyopathy research | NIHR did not commit any specific funding for dilated cardiomyopathy research in 2023-24. | The total commitment across UKRI in 2023-24 for dilated cardiomyopathy research was £1,450,025 for 2 awards (1 award from MRC; 1 award from centrally managed UKRI schemes). |
valvular disease research | NIHR allocated £4,535,107 for research concerning valvular disease research in 2023-24. | The total commitment across UKRI in 2023-24 for valvular disease research was £207,336 for 1 award (from MRC). |
myocarditis | NIHR did not commit any specific funding for myocarditis research in 2023-24. | UKRI did not commit any specific funding for Myocarditis research in 2023-24. |
heart failure research | NIHR allocated £41,442,113 research concerning heart failure research in 2023-24. | The total commitment across UKRI in 2023-24 for heart failure research was £9,893,934 for 20 awards (8 awards from Innovate UK; 4 awards from MRC, 8 awards from centrally managed UKRI schemes, etc), including investigations using AI techniques to develop personalised treatments for heart failure. |
congenital heart disease | NIHR allocated £1,227,966 research concerning congenital heart disease research in 2023-24. | The total commitment across UKRI in 2023-24 for congenital heart disease research was £597,157 for 1 award (from BBSRC). |
coronary heart disease | NIHR allocated £10,722,571 research concerning coronary heart disease research in 2023-24. | The total commitment across UKRI in 2023-24 for coronary heart disease research was £2,234,898 for 3 awards (2 awards from Innovate UK; 1 award from EPSRC). |
ST-elevation myocardial infarction | NIHR did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24. | UKRI did not commit any specific funding for ST-elevation myocardial infarction research in 2023-24. |
non-ST-elevation myocardial infarction | NIHR did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24. | UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24. |
heart block | NIHR allocated £24,667,421 for research concerning heart block in 2023-24. | UKRI did not commit any specific funding for non-ST-elevation myocardial infarction research in 2023-24. |
atrial fibrillation | NIHR allocated £3,270,356 for research concerning atrial fibrillation in 2023-24. | The total commitment across UKRI in 2023-24 for atrial fibrillation research was £6,799,271 for 8 awards (1 award from Innovate UK; 2 awards from EPSRC, 5 awards from centrally managed UKRI schemes). |
hypertension | NIHR allocated £30,552,736 for research concerning hypertension in 2023-24. | The total commitment across UKRI in 2023-24 for hypertension research was £8,311,971 for 12 awards (1 award from Innovate UK; 5 awards from MRC, 6 awards from centrally managed UKRI schemes) including the investigation of medical devices for remote monitoring. |
aortic aneurysm | NIHR allocated £2,833,223 for research concerning aortic aneurysm in 2023-24. | The total commitment across UKRI in 2023-24 for aortic aneurysm research was £1,470,668 for 2 awards (1 award from Innovate UK; 1 award from centrally managed UKRI schemes) |
aortic dissection | NIHR allocated £2,833,223 research concerning aortic dissection research in financial year 2023-24. | UKRI did not commit any specific funding for aortic dissection research in 2023-24. |
That this House notes that an estimated 1.6 million people are living with atrial fibrillation in the UK; acknowledges that atrial fibrillation is a contributing factor in one in five strokes; welcomes the NHS’s commitment to improve the early detection and treatment of atrial fibrillation; further notes NHS England’s commitment to expand access to direct oral anticoagulants to help prevent 21,700 strokes and save 5,400 lives over a three-year period; further acknowledges that anticoagulants carry an increased risk of life-threatening bleeding, particularly within the gastrointestinal tract; recognises that the increase in anticoagulation medication will likely lead to an increased number of associated bleeds; further acknowledges the variation within the management of anticoagulation-associated bleeds; urges the National Institute for Health and Care Excellence to review and update clinical guidelines to improve outcomes within the management of anticoagulation-associated bleeds; and calls on NHS England to establish policies to reduce the variation within the management of anticoagulation-associated bleeds and improve patient outcomes.
That this House notes that an estimated 1.6 million people are living with atrial fibrillation in the UK; acknowledges that atrial fibrillation is a contributing factor in one in five strokes; welcomes the NHS’s commitment to improve the early detection and treatment of atrial fibrillation; further notes NHS England’s commitment...
To ask the Secretary of State for Health and Social Care, whether his Department has plans to undertake an assessment of the impact of the NHS Framework Agreement on Direct Oral Anticoagulants to treat atrial fibrillation, implemented from January 2022.
To ask the Secretary of State for Health and Social Care, whether his Department has plans to undertake an assessment of the impact of the NHS Framework Agreement on Direct Oral Anticoagulants to treat atrial fibrillation, implemented from January 2022.
Information on the number of new patients detected with atrial fibrillation is not collected in the format requested. As of October 2022, 126,000 patients on general practitioner practice atrial fibrillation registers who were eligible for anticoagulation received treatment. The proportion of patients treated with anticoagulation increased by 3% from April to October 2022.
An annual evaluation of the National Health Service commissioning guidance and framework agreement for anticoagulation will be made in the first quarter of 2023/24 when the relevant prescribing and performance data is finalised.
To ask the Secretary of State for Health and Social Care, how many new patients have been (a) detected with atrial fibrillation and (b) treated with an appropriate NICE recommended treatment, since the introduction of the NHS Framework Agreement on Direct Oral Anticoagulants in January 2022.
To ask the Secretary of State for Health and Social Care, how many new patients have been (a) detected with atrial fibrillation and (b) treated with an appropriate NICE recommended treatment, since the introduction of the NHS Framework Agreement on Direct Oral Anticoagulants in January 2022.
Information on the number of new patients detected with atrial fibrillation is not collected in the format requested. As of October 2022, 126,000 patients on general practitioner practice atrial fibrillation registers who were eligible for anticoagulation received treatment. The proportion of patients treated with anticoagulation increased by 3% from April to October 2022.
An annual evaluation of the National Health Service commissioning guidance and framework agreement for anticoagulation will be made in the first quarter of 2023/24 when the relevant prescribing and performance data is finalised.
To ask the Secretary of State for Health and Social Care, which atrial fibrillation-related stroke prevention projects have received Detect, Protect, Perfect pathway funding to date, following the implementation of the initiative in January 2022.
To ask the Secretary of State for Health and Social Care, which atrial fibrillation-related stroke prevention projects have received Detect, Protect, Perfect pathway funding to date, following the implementation of the initiative in January 2022.
In 2022/23, NHS England allocated £30 million to support the Detect, Protect and Perfect in primary care.
This has been allocated to a range of atrial fibrillation-related stroke prevention projects, including community pharmacy atrial fibrillation detection; development of primary care atrial fibrillation community hubs; sponsorship for a cardiovascular disease anticoagulation academy; and an Academic Health Science Network educational programme for healthcare professionals on objectives for patients with atrial fibrillation.
To ask the Secretary of State for Health and Social Care, how much of the NHS England atrial fibrillation entitled the Detect, Protect, Perfect pathway initiatives £40m budget has been allocated in 2022.
To ask the Secretary of State for Health and Social Care, how much of the NHS England atrial fibrillation entitled the Detect, Protect, Perfect pathway initiatives £40m budget has been allocated in 2022.
In 2022/23, NHS England allocated £30 million to support the Detect, Protect and Perfect in primary care.
This has been allocated to a range of atrial fibrillation-related stroke prevention projects, including community pharmacy atrial fibrillation detection; development of primary care atrial fibrillation community hubs; sponsorship for a cardiovascular disease anticoagulation academy; and an Academic Health Science Network educational programme for healthcare professionals on objectives for patients with atrial fibrillation.
To ask the Secretary of State for Health and Social Care, what plans he has to include atrial fibrillation (a) detection, (b) treatment, and (c) management in the upcoming refresh to the NHS Long Term Plan.
To ask the Secretary of State for Health and Social Care, what plans he has to include atrial fibrillation (a) detection, (b) treatment, and (c) management in the upcoming refresh to the NHS Long Term Plan.
Following the autumn statement on 17 November 2022, the Government and NHS England will prepare detailed financial and delivery plans for future years, including for the commitments made in the NHS Long Term Plan. This will include consideration of plans for atrial fibrillation detection, treatment and management. Further information will be available in the new year.
To ask the Secretary of State for Health and Social Care, whether funding from the Detect, Protect, Perfect pathway programme will be shared with local pharmacists to support detection initiatives.
To ask the Secretary of State for Health and Social Care, whether funding from the Detect, Protect, Perfect pathway programme will be shared with local pharmacists to support detection initiatives.
Detect, Protect, Perfect funding is available for local health systems, including community pharmacies. Any proposals must be supported by the relevant integrated care board.
To ask the Secretary of State for Health and Social Care, what steps she is taking to tackle the increase in patients suffering with atrial fibrillation.
To ask the Secretary of State for Health and Social Care, what steps she is taking to tackle the increase in patients suffering with atrial fibrillation.
NHS England’s NHS Health Check programme, which aims to prevent cardiovascular disease, includes an assessment of pulse rhythm through the blood pressure check. The check identifies those most likely to suffer atrial fibrillation, helping them to reduce their risk by losing weight and stopping smoking.
To ask the Secretary of State for Health and Social Care, if he will request updated atrial fibrillation prevalence estimates, which were last published in April 2020.
To ask the Secretary of State for Health and Social Care, if he will request updated atrial fibrillation prevalence estimates, which were last published in April 2020.
The National Cardiovascular Intelligence Network intends to review the methodology for estimates of atrial fibrillation in 2022/23.
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of treating arterial fibrillation with an electric balloon.
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of treating arterial fibrillation with an electric balloon.
NHS England and NHS Improvement advise that this is a new technology which offers an alternative for balloon-based catheter ablation for atrial fibrillation. At present, further research on a wider cohort of patients is required to provide more data and evidence for its use.
To ask the Secretary of State for Health and Social Care, what data his Department holds on detection and diagnosis rates for atrial fibrillation in England (a) from January to May 2019 and (b) from January to May 2020 inclusive; and if he will make a statement.
To ask the Secretary of State for Health and Social Care, what data his Department holds on detection and diagnosis rates for atrial fibrillation in England (a) from January to May 2019 and (b) from January to May 2020 inclusive; and if he will make a statement.
The information is not available in the format requested. The Quality Outcomes Framework reports annually for atrial fibrillation and it is not possible to break down into monthly data.
A register of patients with atrial fibrillation is used to monitor cumulative recorded prevalence year-on-year. Recorded prevalence of atrial fibrillation increased from 1.98% in 2018/19 to 2.05% in 2019/20. Data for 2020/21 will be published during 2021.
To ask the Secretary of State for Health and Social Care, what plans he has to expand the use of digital technologies to improve the remote detection of atrial fibrillation as result of restrictions on face-to-face appointments during the covid-19 outbreak.
To ask the Secretary of State for Health and Social Care, what plans he has to expand the use of digital technologies to improve the remote detection of atrial fibrillation as result of restrictions on face-to-face appointments during the covid-19 outbreak.
The NHS is investing £9 million to fund a demonstrator project to test out new ways of providing treatment to people with Atrial Fibrillation using virtual clinics. NHSX continues to support and encourage emerging innovative diagnostic tools, for example through the Artificial Intelligence Health and Care Awards.